Global Antiviral Therapeutics Market Size Study, By Drug (Hepatitis, Herpes, HIV, Influenza), By Therapy (DNA Polymerase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors, Reverse Transcriptase Inhibitors), By Distribution Channel (Hospital Pharma

Global Antiviral Therapeutics Market Size Study, By Drug (Hepatitis, Herpes, HIV, Influenza), By Therapy (DNA Polymerase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors, Reverse Transcriptase Inhibitors), By Distribution Channel (Hospital Pharmacy, Independent Pharmacy & Drug Store, Online Pharmacy), and Regional Forecasts 2022-2032

The Global Antiviral Therapeutics Market is valued approximately at USD 75.53 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 8.28% over the forecast period 2024-2032. Antiviral therapeutics are specifically designed to target viral pathogens and inhibit their replication, thereby alleviating the symptoms and spread of viral diseases. These drugs are used in various healthcare settings, ranging from hospitals to specialty clinics and home care. They are prescribed for the treatment of diverse viral infections, including influenza, hepatitis, Human Immunodeficiency Virus (HIV), Herpes Simplex Virus (HSV), and the recent SARS-CoV-2. The rising prevalence of various chronic and viral diseases worldwide is expanding the need for antiviral therapeutics.

Growing pharmaceutical research and development activities with increasing healthcare expenditure are driving the growth of the antiviral therapeutics market. Growing research and development activities to develop antiviral therapeutics by market vendors are expected to create opportunities for market growth. The escalating demand for antiviral drugs is significantly attributed to the global surge in the prevalence of viral diseases, necessitating the development of effective therapeutic solutions. Stringent regulatory frameworks emphasizing the safety and efficacy of antiviral medications also contribute to the robust market growth. Despite the challenges posed by the high cost of drug development and potential side effects, advancements in pharmaceutical research and development continue to propel the antiviral therapeutics market forward. Moreover, the integration of novel technologies in drug formulation and delivery is anticipated to enhance the market's growth prospects. However, side effects associated with antiviral drugs and the high cost of development of medication hamper the growth of antiviral therapeutics.

The key regions considered for the global antiviral therapeutics market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is expected to hold a significant share of the market due to the presence of major pharmaceutical companies, advanced healthcare infrastructure, and a high prevalence of viral infections. Europe is also anticipated to contribute significantly to market growth, driven by stringent regulatory standards and substantial healthcare expenditure. The Asia Pacific region is projected to witness the highest growth rate, fueled by increasing investments in healthcare infrastructure, rising awareness about viral diseases, and a large patient population.

Major market players included in this report are:

Abbott Laboratories

AbbVie Inc.

Alkem Laboratories Limited

AstraZeneca PLC

Atea Pharmaceuticals, Inc.

Aurobindo Pharma Limited

Bristol-Myers Squibb Company

Cipla Ltd.

Cocrystal Pharma, Inc.

Daiichi Sankyo Company, Ltd.

Dr. Reddy’s Laboratories Ltd.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

Gilead Sciences, Inc.

GlaxoSmithKline PLC

The detailed segments and sub-segment of the market are explained below:

By Drug:

Hepatitis Antiviral Drug

Herpes Antiviral Drug

HIV Antiviral Drug

Influenza Antiviral Drug

By Therapy:

DNA Polymerase Inhibitors

Non-nucleosides

Purine Nucleoside Analogues

Pyrimidine Nucleoside Analogues

Neuraminidase Inhibitors

Protease Inhibitors

Reverse Transcriptase Inhibitors

By Distribution:

Hospital Pharmacy

Independent Pharmacy & Drug Store

Online Pharmacy

Common content for ‘Report Description’

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Middle East & Africa

Saudi Arabia

South Africa

RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.